Accepted for publication (PostPrint)
Experimental Cell Research
Podoplanin (PDPN) is a transmembrane glycoprotein that promotes tumor cell migration, invasion, and cancer metastasis. In fact, PDPN expression is induced in many types of cancer. Thus, PDPN has emerged as a functionally relevant cancer biomarker and chemotherapeutic target. PDPN contains 2 intracellular serine residues that are conserved between species ranging from mouse to humans. Recent studies indicate that protein kinase A (PKA) can phosphorylate PDPN in order to inhibit cell migration. However, the number and identification of specific residues phosphorylated by PKA have not been defined. In addition, roles of other kinases that may phosphorylate PDPN to control cell migration have not been investigated. We report here that cyclin dependent kinase 5 (CDK5) can phosphorylate PDPN in addition to PKA. Moreover, results from this study indicate that PKA and CDK5 cooperate to phosphorylate PDPN on both intracellular serine residues to decrease cell motility. These results provide new insight into PDPN phosphorylation dynamics and the role of PDPN in cell motility. Understanding novel mechanisms of PDPN intracellular signaling could assist with designing novel targeted chemotherapeutic agents and procedures.
Krishnan, Harini; Retzbach, Edward; Ramirez, Maria; Liu, Tong; Li, Hong; Miller, W.; and Goldberg, Gary, "PKA and CDK5 Can Phosphorylate Specific Serines on the Intracellular Domain of Podoplanin (PDPN) to Inhibit Cell Motility." (2015). School of Osteopathic Medicine Faculty Scholarship. 76.
Krishnan H, Retzbach EP, Ramirez MI, Liu T, Li H, Miller WT, Goldberg GS. PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility. Exp Cell Res. 2015 Jul 1;335(1):115-22. Epub 2015 May 7. doi: 10.1016/j.yexcr.2015.04.019. PMID: 25959509. PMCID: PMC4556139.